December 12: Senores Pharmaceuticals, Inc. announced
the launch of Deferiprone Tablets USP, 500 mg & 1000 mg, which is bioequivalent and
therapeutically equivalent to Ferriprox Tablets of Chiesi USA, Inc. in the U.S. market. The product will
be marketed by Dr. Reddy& 39;s Laboratories Inc.
“We are pleased to advance our growth with the launch of a limited-competition product. This aligns
with our strategic focus on identifying and entering a niche, under-penetrated generic formulations
with an opportunity to serve the unmet needs in healthcare” stated Swapnil Shah, Managing
Director, Senores Pharmaceuticals Limited.
Deferiprone Tablets, 500 mg & 1000 mg brand and generic products, had U.S. sales of approximately
$70 million MAT for the twelve months ending in October 2025 according to symphony.
